The identification of high penetrance alleles of the BRCA1 (MIM 113705) and BRCA2 (MIM 600185) genes, which determine a high risk of developing hereditary breast and ovarian cancer, has made genetic testing an integral part of oncogenetic counseling in clinical practice [1,2,3,4,5,6]. This evidence concerns the gene BRCA1 and ovarian cancer.